Skip to content
    Deep Track Capital logo

    Deep Track Capital

    Greenwich, Connecticut, United StatesFounded 2020
    www.deeptrackcapital.com
    Biotech & Life Sciences

    Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. It develops long-term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies.

    63% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (41% of deals). Average disclosed round size is $129.7M (across 62 rounds with reported amounts).

    Find people at Deep Track Capital on Goldilocks AI

    Portfolio

    56

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    11

    Team

    BE

    Brett Erkman

    Managing Director

    GS

    Gerard Smith, MD/MBA

    Managing Director

    RM

    Rael Mazansky, MD/MBA

    Managing Director

    RL

    Rebecca Luse

    Managing Director

    DB

    Daniel Berke, JD

    Senior Compliance Associate

    DK

    David Kroin

    Founder and Chief Investment Officer

    AH

    Aaron Hakim, MD

    Exclusive Consultant

    BD

    Brian Diminich, CPA/MBA

    Senior Controller

    EF

    Estelle Forstbauer

    Executive Assistant

    JJ

    Jeremy Joseph, CFA

    Head of Business Development andInvestor Relations

    NM

    Nir Messafi, CPA

    Chief Operating and Financial OfficerChief Compliance Officer

    SV

    Sarette Verdeschi

    Executive Assistant & Office Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    70 investments
    CompanyRoundAmountDate
    Draig Therapeutics logoDraig TherapeuticsSeries B$65MJul 2026
    Oblenio Bio logoOblenio BioSeries B$62MJun 2026
    cAMPfield Therapeutics logocAMPfield TherapeuticsSeries A$180MJun 2026
    CcAMPfieldSeries A$180MJun 2026
    TTriveniSeries C$65MJun 2026
    Terremoto Biosciences logoTerremoto BiosciencesSeries C$108MApr 2026
    Ambrosia Biosciences Inc. logoAmbrosia Biosciences Inc.Series B$100MMar 2026
    CcAMPfieldSeries A$180MJan 2026
    cAMPfield Therapeutics logocAMPfield TherapeuticsSeries A$180MJan 2026
    Ambrosia Bio logoAmbrosia BioSeries B$100MJan 2026
    HHemabSeries C$157MOct 2025
    Tubulis logoTubulisSeries C—Oct 2025
    TTubulis GmbHSeries C—Oct 2025
    Avenzotx logoAvenzotxSeries B$60MSep 2025
    Crescent Biopharma logoCrescent BiopharmaGrowth$200MJun 2025
    Attovia Therapeutics logoAttovia TherapeuticsSeries C$90MApr 2025
    Imbria Pharmaceuticals logoImbria PharmaceuticalsSeries B$57.5MApr 2025
    IImbriaUnknown$57.5MApr 2025
    Arbor Biotechnologies logoArbor BiotechnologiesSeries C$73.9MMar 2025
    Latigo Biotherapeutics logoLatigo BiotherapeuticsSeries B$150MMar 2025
    Avenzo Therapeutics logoAvenzo TherapeuticsSeries B$60MJan 2025
    IImbriaSeries B$57.5MJan 2025
    Imbria Pharmaceuticals logoImbria PharmaceuticalsSeries B$59.2MJan 2025
    RAPT Therapeutics logoRAPT TherapeuticsSeries D$150MDec 2024
    35 Pharma logo35 PharmaSeries C$53MNov 2024
    Page 1 of 3

    Top Co-Investors

    RA Capital Management34 shared
    Surveyor Capital19 shared
    Frazier Life Sciences17 shared
    OrbiMed17 shared
    The Invus Group, LLC15 shared
    Logos Capital12 shared
    Cormorant Asset Management11 shared
    Access Biotechnology11 shared
    Venrock Healthcare Capital Partners11 shared
    Sofinnova Partners11 shared
    Atlas Venture11 shared
    Rock Springs Capital10 shared
    Wellington Management10 shared
    RTW Investments, LP9 shared
    Foresite Capital8 shared
    Samsara BioCapital8 shared
    Novo Capital8 shared
    Piper Heartland Healthcare Capital8 shared
    SV Health Investors8 shared
    SR One7 shared

    Last updated: 7 October 2026